These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11840981)

  • 61. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
    Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
    Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New developments in pituitary surgical techniques.
    Fahlbusch R; Thapar K
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):471-84. PubMed ID: 10909437
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Direct intraoperative micromethod for hormone measurements of pituitary tissue in Cushing's disease.
    Flitsch J; Knappe UJ; Lüdecke DK
    Surg Neurol; 1999 Dec; 52(6):585-90; discussion 590-1. PubMed ID: 10660024
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.
    Losa M; Barzaghi RL; Mortini P; Franzin A; Mangili F; Terreni MR; Giovanelli M
    Am J Pathol; 2000 Jan; 156(1):245-51. PubMed ID: 10623673
    [TBL] [Abstract][Full Text] [Related]  

  • 65. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein.
    Abdollahi A; Bao R; Hamilton TC
    Oncogene; 1999 Nov; 18(47):6477-87. PubMed ID: 10597250
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.
    Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
    J Clin Oncol; 1999 Jul; 17(7):1974-82. PubMed ID: 10561247
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Using database information in your clinical practice.
    Dziuban SW
    Ann Thorac Surg; 1999 Aug; 68(2):350-2; discussion 374-6. PubMed ID: 10475395
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Expression of Rab3, a Ras-related GTP-binding protein, in human nontumorous pituitaries and pituitary adenomas.
    Tahara S; Sanno N; Teramoto A; Osamura RY
    Mod Pathol; 1999 Jun; 12(6):627-34. PubMed ID: 10392640
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Correlates of long-term hypocortisolism after transsphenoidal microsurgery for Cushing's disease.
    Flitsch J; Lüdecke DK; Knappe UJ; Saeger W
    Exp Clin Endocrinol Diabetes; 1999; 107(3):183-9. PubMed ID: 10376443
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Role of gamma knife therapy in the management of pituitary tumors.
    Jackson IM; Norén G
    Endocrinol Metab Clin North Am; 1999 Mar; 28(1):133-42. PubMed ID: 10207688
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytosolic autoantigens in lymphocytic hypophysitis.
    Crock PA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):609-18. PubMed ID: 9467582
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas.
    Blevins LS; Christy JH; Khajavi M; Tindall GT
    J Clin Endocrinol Metab; 1998 Jan; 83(1):63-7. PubMed ID: 9435417
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinico-pathological study of Cushing's disease with large pituitary adenoma.
    Ikeda H; Yoshimoto T; Ogawa Y; Mizoi K; Murakami O
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):669-79. PubMed ID: 9274697
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The c-erbB-2/neu proto-oncogene in human pituitary tumours.
    Ezzat S; Zheng L; Smyth HS; Asa SL
    Clin Endocrinol (Oxf); 1997 May; 46(5):599-606. PubMed ID: 9231056
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A neurological complication of inferior petrosal sinus sampling during investigation for Cushing's disease: a case report.
    Sturrock ND; Jeffcoate WJ
    J Neurol Neurosurg Psychiatry; 1997 May; 62(5):527-8. PubMed ID: 9153615
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing's disease.
    Knappe UJ; Lüdecke DK
    Acta Neurochir Suppl; 1996; 65():31-4. PubMed ID: 8738490
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessment of cure after transsphenoidal surgery for Cushing's disease.
    McCance DR; Besser M; Atkinson AB
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):1-6. PubMed ID: 8706280
    [TBL] [Abstract][Full Text] [Related]  

  • 78. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
    Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
    Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin-secreting adenomas.
    Mamelak AN; Dowd CF; Tyrrell JB; McDonald JF; Wilson CB
    J Clin Endocrinol Metab; 1996 Feb; 81(2):475-81. PubMed ID: 8636253
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hypothalamic-pituitary corticotroph function after shunting of magnocellular vasopressin and oxytocin to the hypophyseal portal circulation.
    Makara GB; Kiss A; Lolait SJ; Aguilera G
    Endocrinology; 1996 Feb; 137(2):580-6. PubMed ID: 8593805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.